Treatment of Panniculitis

Diagnostic Approach

• The American College of Dermatology recommends obtaining a deep excisional biopsy reaching medium-sized vessels and adequate subcutaneous fat tissue to establish the correct diagnosis and direct appropriate therapy, as superficial biopsies frequently miss the pathology and represent the most common diagnostic error 1, 2
• The specimen should be divided for histopathological evaluation to classify as septal versus lobular panniculitis and identify vasculitis, with a strength of evidence level of high 1, 2
• Plasma alpha-1 antitrypsin (AAT) levels should be tested in all cases of biopsy-proven severe panniculitis, particularly those with necrotizing or ulcerative features, as this requires specific augmentation therapy, with a recommendation grade of A 1, 2

Etiology-Specific Treatment

• The American Thoracic Society recommends initiation of augmentation therapy with purified human AAT or fresh frozen plasma as primary treatment for alpha-1 antitrypsin deficiency-associated panniculitis, which restores plasma and local tissue AAT levels and represents the most effective intervention, with a high level of evidence 1, 2
• Dapsone can be added either alone in less severe cases or combined with augmentation therapy for additional therapeutic benefit, with a moderate level of evidence 1, 2
• For subcutaneous panniculitis-like T-cell lymphoma (SPTCL) without hemophagocytic syndrome, the National Comprehensive Cancer Network recommends initiation of systemic corticosteroids or other immunosuppressive agents as first-line therapy, with a 5-year survival of 91%, and a high level of evidence 3, 4, 1
• For SPTCL with hemophagocytic syndrome, the National Comprehensive Cancer Network recommends immediate start of multi-agent chemotherapy due to the aggressive nature, with a 5-year survival dropping to 46%, and a high level of evidence 3, 4, 1
• The American College of Rheumatology recommends treatment with cyclophosphamide combined with high-dose glucocorticoids for polyarteritis nodosa presenting with cutaneous panniculitis, with a moderate level of evidence 1
• For infectious panniculitis (Nocardia), the Infectious Diseases Society of America recommends initiation of sulfamethoxazole-trimethoprim (SMX-TMP) as first-line therapy, with alternative agents including sulfadiazine, amikacin, imipenem, meropenem, ceftriaxone, minocycline, moxifloxacin, linezolid, or dapsone, and a high level of evidence 1

Monitoring Strategy

• The American Academy of Dermatology recommends performing serial clinical examinations focusing on new nodules, ulcerations, or systemic symptoms rather than repeated invasive procedures or imaging, with a moderate level of evidence 1, 2
• For patients with peripheral motor neuropathy secondary to panniculitis, serial neurologic examinations should be used rather than repeated electromyography, with a low level of evidence 1

Critical Pitfalls to Avoid

• Inadequate biopsy depth is the most common diagnostic error—always obtain deep excisional specimens reaching subcutaneous fat and medium-sized vessels, with a high level of evidence 1, 2
• Panniculitis can be lethal, especially when associated with cirrhosis or emphysema in AAT deficiency, or when associated with hemophagocytic syndrome in lymphoma, with a high level of evidence 1
• Do not delay treatment in suspected hemophagocytic syndrome, as this represents a medical emergency requiring immediate multi-agent chemotherapy, with a high level of evidence 3, 4
• Always exclude malignancy-associated panniculitis, which requires treatment of both the underlying neoplasm and any associated hemophagocytic lymphohistiocytosis, with a high level of evidence 1

Caloric Deficit and Dietary Strategies for Weight Reduction in Obese Patients with Panniculitis

Caloric Deficit Targets

• Patients with a body‑mass index (BMI) of 30–34.9 kg/m² should reduce daily energy intake by roughly 500 kcal, which is expected to produce a weight loss of about 0.5 kg (≈1 lb) per week. 5
• Patients with a BMI ≥ 35 kg/m² should aim for a 500–1000 kcal per day energy deficit, targeting a weight loss of 0.5–1 kg (≈1–2 lb) per week. 6

Dietary Implementation Strategies

• Portion‑controlled servings, pre‑packaged meals, or liquid formula replacements are recommended to enhance compliance with the prescribed caloric deficit. 5
• Increase consumption of high‑water‑content foods (e.g., fruits and vegetables) while limiting high‑energy‑density foods to promote satiety and improve nutrient quality. 6

Diagnostic Investigations for Panniculitis

Biopsy Technique

• A deep excisional or “double” punch biopsy that includes subcutaneous fat and medium‑sized dermal vessels is essential because insufficient depth is the most common cause of missed diagnosis in panniculitis. 7
• When polyarteritis nodosa is suspected and peripheral neuropathy is present, a combined nerve‑and‑muscle biopsy of clinically involved tissue is preferred over nerve biopsy alone to improve diagnostic yield. [7][8]

Laboratory Testing

• Baseline measurement of inflammatory markers (erythrocyte sedimentation rate and C‑reactive protein) should be obtained to aid both diagnosis and prognosis of panniculitis. 9
• In cases where lupus panniculitis is considered (e.g., lymphocytic infiltrate on histology), autoantibody screening—including ANA, anti‑dsDNA, and complement levels—should be performed. 9
• HLA‑B27 testing is recommended when clinical features raise suspicion for vasculitis‑associated panniculitis or Behçet‑like disease. 9

Imaging Studies – Vascular

• For patients with suspected polyarteritis nodosa, abdominal vascular imaging (CT angiography or MR angiography) is required to confirm the diagnosis, delineate disease extent, and identify characteristic arterial stenoses or occlusions. 7
• In individuals who have achieved clinical remission of severe panniculitis with prior abdominal vascular involvement, repeat abdominal vascular imaging is advised, especially if the initial study demonstrated aneurysmal disease. 7

Neurologic Assessment

• Initial evaluation of suspected vasculitis‑related panniculitis should include electromyography and nerve‑conduction studies to confirm and characterize any peripheral neuropathy. 7
• Ongoing monitoring of established peripheral motor neuropathy is best performed with serial neurologic examinations rather than repeated electromyography, to reduce patient burden while tracking disease course. 7